Who is sponsoring NCT05250791?

NCT05250791 is sponsored by Imperial College London.

What drugs are being tested in NCT05250791?

Interventions in NCT05250791: Lidocaine hydrochloride 2% for injection, 0.9% sterile Sodium Chloride solution for injection.

What condition does NCT05250791 study?

NCT05250791 studies Colorectal Cancer, Quality of Life, Recurrent Cancer.

Is NCT05250791 still recruiting?

NCT05250791 is currently status unknown. Last updated 9 June 2023.

Last reviewed 2023-06-09 · How we verify

NCT05250791: FLICOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility Study of Lidocaine Infusion During Bowel Cancer Surgery for Cancer Outcome

Status unknown NA Last updated 9 June 2023

What this trial tests

NA trial testing Lidocaine hydrochloride 2% for injection in Colorectal Cancer in 50 participants. Status unknown.

Timeline

2 February 2023

Primary endpoint
15 September 2024

15 September 2024

Quick facts

Lead sponsor	Imperial College London
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	2 February 2023
Primary completion	15 September 2024
Estimated completion	15 September 2024
Sites	2 locations across United Kingdom

Drugs / interventions tested

Lidocaine hydrochloride 2% for injection — full drug profile →
0.9% sterile Sodium Chloride solution for injection — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →
Quality of Life — all drugs for Quality of Life →
Recurrent Cancer — all drugs for Recurrent Cancer →

Sponsor

Imperial College London

Who can join

18 and older, any sex, with Colorectal Cancer or Quality of Life. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This feasibility (small) study aims to see if it is possible to run a large study looking at the effect of lidocaine on large bowel cancer recurrence after surgery in the NHS hospitals.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications.
Pu T, Sun J, Ren G, Li H. · · 2025 · cited 34× · PMID 40456735 · DOI 10.1038/s41392-025-02241-8
The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities.
Zhang C, Guo X, Liu P, Wang Y, et al · · 2025 · cited 6× · PMID 41152924 · DOI 10.1186/s13045-025-01748-5
A protocol for a pilot study to assess the feasibility of a randomised clinical trial of perioperative intravenous lidocaine on colorectal cancer outcome after surgery (FLICOR trial).
West R, Soo CP, Murphy J, Vizcaychipi MP, et al · · 2023 · cited 3× · PMID 37387798 · DOI 10.1016/j.bjao.2023.100138
Anaesthetic Techniques and Strategies: Do They Influence Oncological Outcomes?
Murphy L, Shaker J, Buggy DJ. · · 2023 · cited 3× · PMID 37366886 · DOI 10.3390/curroncol30060403

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05250791 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 9 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05250791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing